探索基因调节网络和潜在的治疗药物基于ELF3表达在胆管癌的胆管癌
Cui Zhang1, Mengting Tong2, Guangpeng Chen3
1Department of Medical Oncology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
概括
在胆管癌 (CCA) 中,ELF3 过度表达,可以作为诊断标记物. 鉴定了共同表达的基因和潜在的药物,为这种致命的癌症提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 胆管癌 (CCA) 是一种严重的癌症,预后生物标志物有限.
- 对于CCA患者,迫切需要改进诊断和治疗策略.
研究的目的:
- 研究ELF3作为CCA中的潜在生物标志物的作用.
- 确定CCA.的共同表达基因和潜在的治疗点.
主要方法:
- 在CCA组织中分析了ELF3表达和促进物甲基化.
- 使用LinkedOmics和STRING数据库识别了共同表达的基因.
- 基因调节网络和潜在药物使用GeneMANIA和CMAP进行了选.
主要成果:
- 在CCA组织中,ELF3表达显著更高,促进物甲基化减少.
- 确定了307个ELF3共同表达的基因,其中61个核心基因与细胞结合和分化有关.
- ELF3网络涉及免疫细胞和细胞粘附;确定了10种潜在药物,包括4种现有的药物.
结论:
- ELF3显示出作为CCA的诊断标记物的潜力.
- 已识别的共同表达的基因和药物为CCA治疗提供了有前途的途径.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...